Relay Therapeutics, Inc. - Common Stock (RLAY)

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

This clinical-stage biotech focused on precision oncology therapies reported an insider sale amid a year of sharp share price gains.

Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering.

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative fervor surrounding a potential multi-billion-dollar acquisition of the company began to dissolve, leaving investors to grapple with a "news

Sometimes insiders sell shares because their conviction is changing. Sometimes it's just about bookkeeping.

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across an array of specialized and niche domains. Far from the public eye, AI is demonstrating unparalleled versatility, solving complex, previously intractable problems and delivering significant impact in areas ranging from accelerated drug [...]

Relay Therapeutics reports Q3 2025 results, missing revenue estimates. The biotech firm maintains a strong cash position to fund its clinical trials for lead drug RLY-2608 into 2029.

The cancer-focused biotech has a bright future, according to one pundit.

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

Investors weren't happy with the company's latest effort at capital-raising.